Pharma channel feed

J&J's block­buster Ste­lara wins US ap­proval for ul­cer­a­tive col­i­tis

6 years ago
R&D
FDA+

As­traZeneca's Farx­i­ga scores FDA nod to cut risk of hos­pi­tal­iza­tion for heart fail­ure in di­a­bet­ics

6 years ago
R&D
FDA+

Alex­ion clinch­es aHUS ap­proval for Ul­tomiris as the clock ticks on Soliris con­ver­sion

6 years ago

EMA backs sev­en ther­a­pies, in­clud­ing Mer­ck­'s Ebo­la vac­cine

6 years ago
R&D
FDA+

J&J's Xarel­to, Amar­in's Vas­cepa are cost-ef­fec­tive, not bud­get friend­ly — ICER

6 years ago
FDA+

With biosim­i­lar threat un­der con­trol (for now), Roche sa­vors de­mand for its new drugs

6 years ago
R&D

CSL ac­cus­es ri­val Pharm­ing of par­tic­i­pat­ing in a scheme to rip off IP on HAE while re­cruit­ing se­nior R&D staffer

6 years ago
R&D

Pa­tient ex­pe­ri­ence da­ta: Sanofi re­searchers call for more con­sis­ten­cy from FDA

6 years ago
FDA+

HR vi­o­la­tion push­es Re­vance co-founder out, vault­ing for­mer Zel­tiq chief to the helm

6 years ago
People

Pelosi drug pric­ing bill promis­es sav­ings, but could gag R&D — CBO analy­sis

6 years ago
R&D

First place fin­ish: Eli Lil­ly just moved to fran­chise leader with their sec­ond mi­graine drug OK in 1 year

6 years ago
R&D

Re­searchers find 15% of tri­als could be repli­cat­ed us­ing re­al world da­ta

6 years ago
R&D

In re­ver­sal, NICE backs Rubra­ca af­ter Clo­vis agrees to a price cut

6 years ago
FDA+

Drug price hikes, with­out jus­ti­fi­able new ev­i­dence of ben­e­fit — ICER analy­sis

6 years ago
R&D

Dif­ferin mak­er Gal­der­ma wins FDA ap­proval for a new retinoid for ac­ne

6 years ago
FDA+

J&J poach­es Bay­er ex­ec Jim Swan­son as chief in­for­ma­tion of­fi­cer

6 years ago
People

King Keytru­da: Mer­ck­'s PD-1 star scores #1 po­si­tion and $22B+ pre­dic­tion in an­oth­er top 10 block­buster list for 2025

6 years ago

Phar­ma to blame for im­peach­ment woes? Yep, Pres­i­dent Trump just sug­gest­ed that about Amer­i­ca's least fa­vorite in­dus­try

6 years ago

Gilead scores PrEP ap­proval for De­scovy — kick­ing off mar­ket­ing push be­fore Tru­va­da gener­ics swarm

6 years ago
FDA+

In an un­usu­al move, ICER re­scinds draft re­port on JAK drugs for rheuma­toid arthri­tis to re­vise its mod­el­ing ap­proach

6 years ago
FDA+

J&J set­tles Ohio opi­oid case for $20.4M, avoids loom­ing tri­al

6 years ago

No­var­tis stacks more pos­i­tive PhI­II da­ta on Cosen­tyx fran­chise — eye­ing ap­proval in non-ra­di­ograph­ic ax­i­al spondy­loarthri­tis

6 years ago
R&D

J&J's em­bat­tled In­vokana gets a boost as FDA ex­pands la­bel

6 years ago
FDA+

Be­yond BR­CA: As­traZeneca rounds out ES­MO with a case for ex­pand­ed bio­mark­er in prostate can­cer

6 years ago
R&D
First page Previous page 264265266267268269270 Next page Last page
A service from the Financial Times